Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
I'd agree that this is share is a mongrel stray dog. It will bite you in the arse when you are least expecting. if you are patient and like a gamble then this share can also pay. The potential deal with Dr.Reddy's evaporating is a bit of a blow and narrow options somewhat. Where the SP will rise is on any mention of a deal with the big pharma currently taking 3 MTPH formulations through IND prep work. The hiring of new staff to support clinical progression was encouraging recently. To me the immediate proposal is a punt on news coming fairly soon regarding the clinical development of one of the Q-sphera assets with said big pharma. The cheaper I can get in on this, the better :-)
Agree, why would you hire a new CMC lead to oversee GMP activities if you weren't supporting taking something new into the clinic sometime soon? Good news!
I'd say that this share is good for milking as long as she doesn't knock over the bucket and kick you in the face. I've had both experiences.
Not sure it really it needed an RNS either, seems OTT. What's next, an RNS on what the CEO had for lunch?
There is an EU patent 'EP3576717 - NANOPARTICLE-BASED LIVER-TARGETING THERAPY ' which the EU patent office intend to grant, dated 29th Nov 2020. https://register.epo.org/application?number=EP18704926 .I wonder if it is this?
This is great news. Obviously a first glimpse into what could be a well needed treatment option for children with DIPG.
There isn't a great deal of survival data for DIPG but literature evidence suggests that median overall survival (OS) is around 10 months with 35% of patients surviving 12 months after diagnosis, or start of treatment (OS12).
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4483042/
It appears in the Midatech study, with a low number of patients and lack of statistical power that median OS is 26 months and OS12 is 71.4% .
A phase II study is needed to prove significance but as Midatech say in the RNS these initial results are encouraging.
P.s. Try to ignore the Emergex stuff, Midatech has made no recent noise about this and the future of this company is tied to other assets. Saying this, we cannot rule out the Emergex deal bearing fruit, it's just too speculative at the moment as nothing is really known.
Hi groose. If you want to see a summary of what to expect in the short to mid term please look down the board for Viveka's posts. They are comprehensive, balanced and based in fact in my opinion. This company can reward you but isn't for the faint hearted so definitely do your own homework before investing.
The next news should be headline results for the MTX110 trial. RNS dated 10th Sep: "Our initial Phase I study in DIPG patients is being conducted by the University of California, San Francisco and is expected to report safety, tolerability and a recommended dose for Phase II within the next few weeks". Based on this, news may arrive next week or the week after. The results should hopefully be mostly positive (should report a higher tolerated dose of panobinostat for use in the subsequent efficacy study). Not sure if it will move the SP that much but I'm hoping it stays north of 30p.
Looks about right at the moment at $1.97. The arbitrageurs won't be knocking quite yet..... :-)
No problem NicetoMichu. Stamp got a bit caught off guard when he was asked 'why didn't you adopt this company strategy in the first place'. His answer was a bit awkward but to be fair it wasn't on his watch.....
* correction Q sphera partnering decisions = 1Q2021
The investor call was actually quite enlightening. Information of note was:
1) IND enabling studies need to be performed by partners before any deals can be struck with the Q-Sphera tech. This pre-clincial work will take time and decisions are not anticipated until 1Q2020.
2) Secura Bio continue to withhold the panobinostat license from Midatech and will not reconsider. Options are to go to court ($2-4 milion plus 2-3 years) or wait until the patent expires (3 years). Midatech feel that the terms of the license are not great anyway so may opt for patent expiry before launch..... Stamp said they will probably not pursue in court.
3) SME status has not been given to Midatech by EU because when they applied CMS owned >50% of the shares in the company. CMS is a large and wealth company so EU viewed MIdatech in the same way. CMS only own 17% of company now so Midatech is hoping to resolve this.
Aside from the financials, which we kind of knew already, we would't expect there to be any news of significance in this routine report. Companies that are listed have to report significant news as and when it arises. It seems that the SP has dropped a bit after hopefuls have realised that there aren't any nuggets in the release. What might be interesting is the investor call at 2pm. I'm really hoping to get a timeline for news rather than news itself (more news would be nice but I'm not expecting anything significant). I'm going to dial into the call so with post back later if there's any new info.
Unfortunately I think the AIM SP might sink to ~30p in the near future but should hopefully find support there (or test it at least). According to the latest RNS it seems that there is an investor relations webinar on the 10th Sep. I'm hoping that at least rough timings around the information flow can be shared here to stem the SP haemorrhage.
Without news for a while (and the US going on unexpected bull runs) this SP will lose value like an inflatable dartboard loses air. We need news pretty soon to repair the puncture. Not sure why with a plethora of potential activities / read-outs there is none.
This share remains illiquid and volatile (in either way). Lack of substantial news will erode support over time. We can probably expect about an inter-day +/- 10-15% variance in the SP, without any excitement. Any more then I'd say something was happening. If any significant positive news drops then this SP will rise very quickly and quite far. If any negative news drops it will do the opposite. I've started calling this my 'casino share', not that AIM is ever much more than a gamble anyway...
**Typo: Ordinary SP = (ADR/5)*0.76 ...not 0.74 (not that it matters that much...
Latino, the US price isn't too far off the UK price. $3.60 / ADR = ~£0.55p / ordinary share, i.e. 5 UK shares = 1 ADR, $ to £ exchange rate is 0.76. Ordinary share price equivalent = (ADR/5)*0.74 the US rise has in part corrected for price but as I type it seems to be going higher so who knows where it will end up.
I agree, I can't keep up with the price in the US, volume of trades looks bonkers, rise looks good!!